Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

Inclusion Criteria: * Male or female \>18 years of age at time of enrollment * Clinical diagnosis of stable plaque type psoriasis * Two target plaques of similar severity meeting the following criteria: * 5 cm2 and ≤ 100 cm2, computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter Bilaterally located (right/left) plaques on the arms or plaques located on the trunk. Plaques located on the trunk must be separated by at least 10 cm Overall target plaque severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point difference in the scores of the two target plaques * Willing and able to apply study drug as directed, comply with study instructions and commit to all follow-up visits * Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures Exclusion Criteria: * Any dermatological conditions, disease state or physical condition that could interfere with clinical evaluations or might expose the patient to an unacceptable risk by study participation * Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below) * Clinically significant, abnormal Screening laboratory results (unless approved by the medical monitor) * Known sensitivity to any of the components of the study medication * Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis * Concomitant use of topical or systemic therapies that might alter the course of psoriasis * Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (hysterectomy or bilateral oophorectomy) * Washout periods for exclusionary therapies: Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks Topical drugs that might alter the course of psoriasis: 2 weeks Use of emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit * AIDS or AIDS-related illness * Concurrent participation in another drug or device research study or within 30 days prior to enrollment * Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil) * Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been stabilized for at least 3 months * Use of AN2728 in a previous clinical trial